Kits for multiparametric phospho analysis
As disclosed herein, the present invention provides for kits and a composition for diagnosis, prognosis, drug discovery, drug development, and patient stratification. The kits can comprise a plurality of binding elements for cell surface markers, and a plurality of binding elements for state-specific intracellular markers. The kits can further comprise a plurality of modulators directed for the particular cell function or signaling pathways. The kits can further include fixatives, permeabilizing agent, buffers, containers, instructions, and software for data analysis/compilation.
1. A kit comprising:
(i) at least one antibody specific for a cell surface marker, wherein said cell surface marker is: CD45;
(ii) at least three antibodies specific for three of the following intracellular markers: Cyclin B1, p-Histone H3, and p-21; and
(iii) at least two of the following modulators: Azacitidine and Decitabine.
2. The kit of claim 1 further comprising at least one dye of Annexin-V, Yo-Pro, or propidium iodide (PI).
3. The kit of claim 1 further comprising a control cell and/or a control compound.
4. The kit of claim 1 further comprising a protocol.
5. The kit of claim 1 further comprising software for data analysis.
6. The kit of claim 1 wherein said kit is used in diagnosis or prognosis of a condition, or drug discovery, drug development or patient stratification for a condition.
7. The kit of claim 6 , wherein said condition is one of non-Hodgkin's lymphoma, Hodgkin's lymphoma, non-B cell lymphomas, other lymphomas, acute or chronic leukemias, polycythemias, thrombocythemias, myelodysplastic disorders, myeloproliferative disorders, myelofibroses, atypical immune lymphoproliferations or a plasma cell disorder.
8. The kit of claim 7 , wherein said plasma cell disorder is multiple myeloma, amyloidosis or Waldenstrom's macroglobulinemia.
9. The kit of claim 7 , wherein said one of acute or chronic leukemias is a myeloid leukemia or a lymphoid leukemia.
10. The kit of claim 9 , wherein said myeloid leukemia is acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), or juvenile myelomonocytic leukemia (JMML).
11. The kit of claim 9 , wherein said lymphoid leukemia is non-B cell acute lymphocytic leukemia (T-ALL), B cell acute lymphoblastic leukemia, or chronic lymphocytic leukemia (CLL).
12. The kit of claim 6 wherein said condition is a hematologic disease or disorder selected from the group consisting of, myelodysplastic disorders, myeloproliferative disorders, myelofibroses, polycythemias, thrombocythemias, B cell immunoproliferations, post transplant lymphoproliferation disorder (PTLD), and non-B atypical immune lymphoproliferations.
13. The kit of claim 6 , wherein said condition is CLL.
14. The kit of claim 6 , wherein said condition is AML.
15. The kit of claim 6 , wherein said condition is acute lymphocytic leukemia (ALL).
16. The kit of claim 6 , wherein said condition is CML.
17. The kit of claim 6 , wherein said condition is a myelodysplastic syndrome (MDS).